PEM POST 04-2024/25 | Quality Variations | Communication to industry | 11/11/2024 | 1 | General ECTD & human medicines, PEM Post-Reg | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines pem-post-reg |
HPA16-2024/25 | SAHPRA Engagement Portal | Communication to industry | 07/11/2024 | 1 | General ECTD & human medicines, HPA | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines hpa |
HPA15-2024/25 | Implementation of Regulatory Information Management System – Information on eCTD 3.1 Module 1 – Document Matrix | Communication to industry | 29/10/2024 | 8 | General ECTD & human medicines, HPA | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines hpa |
HPA15-2024/25 | Communication to Industry – Implementation of RIMS – Information on eCTD 3.1 Module 1 | Communication to industry | 25/10/2024 | 7 | General ECTD & human medicines, HPA | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines hpa |
CLINPR02-2024/25 | Phenylephrine Lack of Effectiveness of Oral Preparations as Nasal Decongestant | Communication to industry | 01/08/2024 | 1 | Clinical Evaluations Management, General ECTD & human medicines | pdf | Download | communication-to-industry | clinical-evaluations-management general-ectd-human-medicines-guidelines |
CLINPR01-2024/25 | Restriction on Codeine Use in Children, Pregnant and/or Breastfeeding Mothers | Communication to industry | 01/08/2024 | 1 | Clinical Evaluations Management, General ECTD & human medicines | pdf | Download | communication-to-industry | clinical-evaluations-management general-ectd-human-medicines-guidelines |
PEM-POST-02-2024_25 | Communication to Industry – FAQs on Active Pharmaceutical Ingredient | Communication to industry | 23/07/2024 | 1 | General ECTD & human medicines | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines |
PEM-POST-01-2024/25 | Frequently asked questions (FAQs) and common deficiencies for the submission of PEM Post-Registration variations | Communication to industry, FAQ | 23/07/2024 | 5 | General ECTD & human medicines, PEM Post-Reg | pdf | Download | communication-to-industry faq | general-ectd-human-medicines-guidelines pem-post-reg |
HPA-15 | Communication to Industry – Implementation of the Regulatory Information Management System, Version 5 Portal & Interim DVP use | Communication to industry | 09/07/2024 | 5 | General ECTD & human medicines, HPA | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines hpa |
HPA-16 | ZA-SAHPRA CTD eSubmission Specification – Document for comment | Communication to industry | 06/06/2024 | 3 | General ECTD & human medicines, HPA | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines hpa |
HPA-15 | Communication to Industry – Implementation of Regulatory Information Management System – Update on Progress | Communication to industry | 28/05/2024 | 6 | General ECTD & human medicines, HPA | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines hpa |
HPA-15 | Communication to Industry – Implementation of Regulatory Information Management System – Responses to queries in eSubmission format | Communication to industry | 29/04/2024 | 3 | General ECTD & human medicines, HPA | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines hpa |
HPA-15 | Communication to Industry – Implementation of Regulatory Information Management System (RIMS) – Update on Progress | Communication to industry | 29/04/2024 | 2 | General ECTD & human medicines, HPA | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines hpa |
PEM_Preg_01-2024/25 | EDQM CEP 2.0 Implementation | Communication to industry | 29/04/2024 | 1 | General ECTD & human medicines, PEM Pre-Reg, Pharmaceutical Evaluation Management | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines pem-pre-reg pharmaceutical-evaluation-management |
HPA-15 | Communication to Industry – Implementation of Regulatory Information Management System | Communication to industry | 06/03/2024 | 1 | General ECTD & human medicines, HPA | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines hpa |
HPA13 | Digital Variations Portal (DVP) User Changes | Communication to industry | 11/07/2023 | 1 | General ECTD & human medicines | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines |
HPA-08 | FAQs on Medicine Registration Renewals | Communication to industry | 22/08/2023 | 5 | General ECTD & human medicines, HPA | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines hpa |
PEM03-2022/23 | Implementation of the QOS and QIS | Communication to industry | 23/05/2023 | 1 | General ECTD & human medicines, PEM Pre-Reg, Pharmaceutical Evaluation Management | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines pem-pre-reg pharmaceutical-evaluation-management |
HPA-11 | Communication on Hard Copy Registration Certificates | Communication to industry | 17/02/2023 | 1 | General ECTD & human medicines, HPA | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines hpa |
HPA-10 | Communication to Industry – Pilot Application Process through the SAHPRA Service Desk | Communication to industry | 01/02/2023 | 1 | General ECTD & human medicines, HPA | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines hpa |
HPA01-2022 | Medicines Registration Renewals Implementation Framework | Communication to industry | 31/07/2024 | 7 | General ECTD & human medicines | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines |
HPA09 | Pre-registration veterinary medicines tracker guide | Communication to industry | 08/12/2022 | 1 | General ECTD & human medicines, Veterinary medicines | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines veterinary-medicines |
| Certification Variation Screening – Type II Proprietary Name Change Applications and TOAs | Communication to industry | 14/12/2022 | 2 | General ECTD & human medicines | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines |
| Expression of Interest-WHO Pre-Qualification Collaborative Registration Procedure | Communication to industry | 17/11/2022 | 1 | General ECTD & human medicines | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines |
HPA07 | Certification Variation Screening – Type II Proprietary name change applications and TOA’s | Communication to industry | 20/10/2022 | 1 | General ECTD & human medicines | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines |
| Position Paper – Proposal to Applicants for Dossier Processing Fee (ZaZiBoNa) | Communication to industry | 13/10/2022 | 1 | General ECTD & human medicines | docx | Download | communication-to-industry | general-ectd-human-medicines-guidelines |
| Over-arching: Good Review Practice Guide | Communication to industry, Guide | 24/06/2022 | 1 | Corporate, General ECTD & human medicines | pdf | Download | communication-to-industry guide | corporate general-ectd-human-medicines-guidelines |
| Extension on commentary period for Borderline Products Guideline | Communication to industry | 15/09/2022 | 1 | Corporate, General ECTD & human medicines | pdf | Download | communication-to-industry | corporate general-ectd-human-medicines-guidelines |
| Missing Applications – Call to Industry | Communication to industry | 18/08/2022 | 1 | Corporate, General ECTD & human medicines, Information Technology | pdf | Download | communication-to-industry | corporate general-ectd-human-medicines-guidelines information-technology |
| Expression Of Interest: SADC Medicines Regulatory Worksharing, Zazibona Collaborative Process | Communication to industry, Expression of interest | 24/10/2019 | 1 | General ECTD & human medicines | pdf | Download | communication-to-industry expression-of-interest | general-ectd-human-medicines-guidelines |
PEM01-2024/25 | Communication to Industry on Nitrosamine Review for New Applications and Registered Products including Biologicals | Communication to industry | 15/05/2024 | 2 | General ECTD & human medicines | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines |
| Retention Fee Notification – 9 June 2022 | Communication to industry | 24/06/2022 | 1 | Biological Medicines, General ECTD & human medicines, Inspectorate and good manufacturing practices, Medical Devices | pdf | Download | communication-to-industry | biological-medicines-evaluation-and-research general-ectd-human-medicines-guidelines inspectorate-and-good-manufacturing-practices medical-devices |
| Payment of annual retention fees for registered products | Communication to industry | 25/05/2022 | 1 | General ECTD & human medicines | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines |
HPA03 | Priority Review Requests Communication | Communication to industry | 11/12/2023 | 3 | General ECTD & human medicines | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines |
| Communication to industry on Clones and Replicas | Communication to industry | 26/11/2020 | 1 | General ECTD & human medicines | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines |
2.19 | Communication to industry on metformin-containing medicines | Communication to industry | 22/10/2020 | 1 | General ECTD & human medicines | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines |
2.18 | Communication to industry on ranitidine-containing medicines | Communication to industry | 21/10/2020 | 1 | General ECTD & human medicines | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines |
2.17 | Communication to industry on the sartans-containing medicines | Communication to industry | 22/10/2020 | 2 | General ECTD & human medicines | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines |
| SAHPRA INVOLVEMENT IN THE SWISSMEDIC MARKETING AUTHORISATION FOR GLOBAL HEALTH PRODUCTS (MAGHP) PROCEDURE | Communication to industry | 23/11/2021 | 1 | General ECTD & human medicines | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines |
9.129 | Re-submission of BAU New Medicines Applications from 2018 and 2019 | Communication to industry | 20/10/2021 | 2 | General ECTD & human medicines | | Download | communication-to-industry | general-ectd-human-medicines-guidelines |
9.128 | Pilot: BAU new medicine applications for registration | Communication to industry | 21/07/2021 | 2 | General ECTD & human medicines | | Download | communication-to-industry | general-ectd-human-medicines-guidelines |
9.127 | eCTD Implementation roadmap communication | Communication to industry | 27/10/2021 | 2 | General ECTD & human medicines | | Download | communication-to-industry | general-ectd-human-medicines-guidelines |
SAHPGL-HPA-05 | BAU Variations Communication | Communication to industry | 07/09/2022 | 4 | General ECTD & human medicines, HPA | pdf | Download | communication-to-industry | general-ectd-human-medicines-guidelines hpa |
| Industry Communication on Interim Measures Pending Update of Variation Addendum | Communication to industry, Guideline | 10/09/2020 | 1 | General ECTD & human medicines | pdf | Download | communication-to-industry guideline | general-ectd-human-medicines-guidelines |